Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models

Nuclear Medicine and Biology

Volumn 33, Issue 6, 2006, Pages 743-750

  Tanaka, Takeshi ^a   Furukawa, Takako ^a   Fujieda, Shigeharu ^a   Kasamatsu, Shingo ^a   Yonekura, Yoshiharu ^a   Fujibayashi, Yasuhisa ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Cancer imaging; Cu ATSM; FDG; Hypoxia; Immunohistochemistry

Indexed keywords

ANIMALS; AUTORADIOGRAPHY; COPPER RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; THIOSEMICARBAZONES;

EID: 33747341325     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.05.005     Document Type: Article

References (38)

1. Pitson G., Fyles A., Milosevic M., Wylie J., Pintilie M., and Hill R. Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer. Int J Radiat Oncol Biol Phys 51 (2001) 699-703
2. Brown J.M. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59 (1999) 5863-5870
3. Fujibayashi Y., Taniuchi H., Yonekura Y., Ohtani H., Konishi J., and Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38 (1997) 1155-1160
4. Fujibayashi Y., Cutler C.S., Anderson C.J., et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol 26 (1999) 117-121
5. O'donoghue J.A., Zanzonico P., Pugachev A., et al. Assessment of regional tumor hypoxia using (18)F-fluoromisonidazole and (64)Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po(2) probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61 (2005) 1493-1502
6. Burgman P., Odonoghue J.A., Humm J.L., and Ling C.C. Hypoxia-Induced increase in FDG uptake in MCF7 cells. J Nucl Med 42 (2001) 170-175
7. Dearling J.L., Flynn A.A., Sutcliffe-Goulden J., et al. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med 45 (2004) 101-107
8. Zhao S., Kuge Y., Mochizuki T., Takahashi T., et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 46 (2005) 675-682
9. Obata A., Yoshimoto M., Kasamatsu S., et al. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG. Nucl Med Biol 30 (2003) 529-534
10. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996) 88-91
11. Nagarajah N.S., Vigneswaran N., and Zacharias W. Hypoxia-mediated apoptosis in oral carcinoma cells occurs via two independent pathways. Mol Cancer 3 (2004) 38
12. Pan Y., Oprysko P.R., Asham A.M., Koch C.J., and Simon M.C. p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment. Oncogene 23 (2004) 4975-4983
13. Obata A., Kasamatsu S., McCarthy D.W., et al. Production of therapeutic quantities of (64)Cu using a 12 MeV cyclotron. Nucl Med Biol 30 (2003) 535-539
14. Obata A., Yoshimi E., Waki A., et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 15 (2001) 499-504
15. Hamacher K., Coenen H.H., and Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27 (1986) 235-238
16. Scholzen T., and Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 182 (2000) 311-322
17. Fujieda S., Sunaga H., Tsuzuki H., Tanaka N., and Saito H. Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma. Clin Cancer Res 4 (1998) 1583-1590
18. Sporn L.A., Chavin S.I., Marder V.J., and Wagner D.D. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest 76 (1985) 1102-1106
19. Fujieda S., Inuzuka M., Tanaka N., et al. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int J Cancer 84 (1999) 315-320
20. Pugachev A., Ruan S., Carlin S., et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 62 (2005) 545-553
21. Bos R., van Der Hoeven J.J., van Der Wall E., et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20 (2002) 379-387
22. Zasadny K.R., Tatsumi M., and Wahl R.L. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 30 (2003) 274-280
23. Schroeder T., Yuan H., Viglianti B.L., et al. Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res 65 (2005) 5163-5171
24. Amellem O., Sandvik J.A., Stokke T., and Pettersen E.O. The retinoblastoma protein-associated cell cycle arrest in S-phase under moderate hypoxia is disrupted in cells expressing HPV18 E7 oncoprotein. Br J Cancer 77 (1998) 862-872
25. Webster L., Hodgkiss R.J., and Wilson G.D. Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo. Br J Cancer 77 (1998) 227-234
26. Cuisnier O., Serduc R., Lavieille J.P., Longuet M., Reyt E., and Riva C. Chronic hypoxia protects against gamma-irradiation-induced apoptosis by inducing bcl-2 up-regulation and inhibiting mitochondrial translocation and conformational change of bax protein. Int J Oncol 23 (2003) 1033-1041
27. Yokoi K., and Fidler I.J. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 10 (2004) 2299-2306
28. Koong A.C., Denko N.C., Hudson K.M., et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res 60 (2000) 883-887
29. Sipos B., Weber D., Ungefroren H., et al. Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: an in vitro and in vivo study. Int J Cancer 102 (2002) 592-600
30. Kinoshita M., Johnson D.L., Shatney C.H., Lee Y.L., and Mochizuki H. Cancer cells surviving hypoxia obtain hypoxia resistance and maintain anti-apoptotic potential under reoxygenation. Int J Cancer 91 (2001) 322-326
31. Koritzinsky M., Wouters B.G., Amellem O., and Pettersen E.O. Cell cycle progression and radiation survival following prolonged hypoxia and re-oxygenation. Int J Radiat Biol 77 (2001) 319-328
32. Dong Z., and Wang J. Hypoxia selection of death-resistant cells. A role for Bcl-X(L). J Biol Chem 279 (2004) 9215-9221
33. Dehdashti F., Mintun M.A., Lewis J.S., et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 30 (2003) 844-850
34. Dehdashti F., Grigsby P.W., Mintun M.A., Lewis J.S., Siegel B.A., and Welch M.J. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys 55 (2003) 1233-1238
35. Chao K.S., Bosch W.R., Mutic S., et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49 (2001) 1171-1182
36. Lewis J., Laforest R., Buettner T., et al. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): an agent for radiotherapy. Proc Natl Acad Sci U S A 98 (2001) 1206-1211
37. Aft R.L., Lewis J.S., Zhang F., Kim J., and Welch M.J. Enhancing targeted radiotherapy by copper(II)diacetyl-bis(N4-methylthiosemicarbazone) using 2-deoxy-d-glucose. Cancer Res 63 (2003) 5496-5504
38. Obata A., Kasamatsu S., Lewis J.S., et al. Basic characterization of 64Cu-ATSM as a radiotherapy agent. Nucl Med Biol 32 (2005) 21-28